Pharmaceuticals, Biotechnology and Life Sciences
Mainz Biomed has reported half year results, in which the main point was expanding international commercialization for its colorectal cancer detenction test, ColoAlert, which in turn has seen revenues for the first six months of 2023 at $499 049, representing an increase of 108% compared to the first half of 2022.
BioNTech and US based OncoC4 today announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). The trial is part of BioNTech’s strategy to initiate multiple pivotal trials in 2023 and 2024, the companies said in a press release Thursday.
Italfarmaco Group said Thursday that submission based on completed Phase 3 program in 179 boys has demonstrated significant slowing of disease progression with a good safety and tolerability profile. The company said that the PDUFA goal date set for December 21, 2023.
Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
NetScientific, the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2023 Notice of Annual General Meeting sent to shareholders were duly passed at the Company’s Annual General Meeting held earlier today. Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution.
Sanofi announced Tuesday the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus.
In recent years, there has been an industry-wide recognition of the need for speed and agility. Accelerating the trial processes for COVID-19 vaccine candidates required proactive and cooperative efforts from participants at all points in the supply chain. A sense of urgency and an expectation that trials should be completed more quickly and effectively emerged as a result of the realization that a drug can be approved and released to the market in a relatively short period of time. In light of this, improving the speed, accuracy, and agility of clinical trials labeling — and more specifically, the translation of label content — is one of the crucial areas that would help organizations to achieve this.
Inceptua Early Access, a business unit of the Inceptua Group, said it has teamed up with Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company, to make Sentynl’s Nulibry available via an Early Access Program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A.
Dupixent presented detailed data at this year’s UEG Week conference in Vienna from from an investigational Phase 3 trial showing positive results in children ages 1 to 11 years old who are living with eosinophilic esophagitis (EoE). EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, approximately 9,000 are most in need of new treatment options.
Vetter, a globally leading contract development and manufacturing organization (CDMO) with long-term experience in supporting biotechnology and pharmaceutical customers, has in place a comprehensive sustainability strategy that has made it a pioneer in this energy-intensive industry.